



HEALTH CARE FUND

OVERALL MORNINGSTAR RATING[‡]

Morningstar rated the Lord Abbett Health Care Fund class A share 3 and 4 stars among 158 and 146 Health Funds for the overall rating and the 3 and 5 year periods ended 9/30/2024, respectively. Morningstar Rating for other share classes may have different performance characteristics. Morningstar ratings are based on risk-adjusted returns and do not take into account the effect of sales charges and loads. See additional information on next page. © 2024 Morningstar, Inc. All Rights Reserved. The information contained: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

LOWER EXPENSES - CLASS A

Fund Expense Ratio ^{1†}	1.03%
Category Average ²	1.37%

INVESTMENT OBJECTIVE

The Fund's investment objective is to seek long-term capital appreciation.

PORTFOLIO CHARACTERISTICS

Number of Holdings: 61
Wtd. Avg. Market Cap (\$B): \$158.7
Price/Earnings Ratio: 46.1x

FUND SYMBOLS/CUSIPS

Class A:	LHCAX	54400A233
Class C:	LHCCX	54400A225
Class F:	LHCFX	54400A217
Class F3:	LHCOX	54400A191
Class I:	LHCIX	54400A183
Class R3:	LHCQX	54400A167
Class R4:	LHCSX	54400A159
Class R5:	LHCTX	54400A142
Class R6:	LHCVX	54400A134

Not all share classes are available to all investors. Please see prospectus for more information.

AVERAGE ANNUAL TOTAL RETURNS (%) AS OF 09/30/2024

CLASS A SHARES	YTD	1 YEAR	3 YEARS	5 YEARS	SINCE INCEPTION	EXPENSE RATIOS ¹	
						Gross	Net [†]
Net Asset Value (without sales charge)	12.84	22.86	1.52	11.99	10.01		
Maximum Offering Price (with 5.75% sales charge)	6.37	15.82	-0.46	10.67	8.75	3.53%	1.03%

CALENDAR YEAR TOTAL RETURNS AT NAV (%)

	2020	2021	2022	2023
NAV	37.13	8.24	-12.03	2.93

Reflects the percent change in net asset value (NAV) of Class A shares and includes the reinvestment of all distributions. Performance is shown for each calendar year. Performance of Class A shares with sales charge reflects the reinvestment of all distributions and includes initial maximum sales charge. Certain purchases of Class A shares without a sales charge are subject to a contingent deferred sales charge (CDSC). The CDSC is not reflected in the performance shown. Returns for less than one year are not annualized. Instances of high double-digit returns were achieved primarily during favorable market conditions and may not be sustainable over time.

Performance data quoted reflect past performance and are no guarantee of future results. Current performance may be higher or lower than the performance quoted. The investment return and principal value of an investment in the Fund will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than their original cost. You can obtain performance data current to the most recent month-end by calling Lord Abbett at 888-522-2388 or referring to lordabbett.com.

¹Reflects expenses for the Fund's fiscal year end and is subject to change. Fund expenses may fluctuate with market volatility. A substantial reduction in Fund assets (since its most recently completed fiscal year), whether caused by market conditions or significant redemptions or both, will likely cause total operating expenses (as a percentage of Fund assets) to become higher than those shown.

²Reflects the average net expenses of Class A shares of all funds within the Lipper Health/Biotechnology Funds Category based on Lipper data available.

A Note About Risk: The value of investments in equity securities will fluctuate in response to general economic conditions and to changes in the prospects of particular companies, including market, liquidity, currency, and political risks. Because the Fund invests a significant portion of its assets in securities issued by health care-related companies, developments affecting the health care industry will likely have a disproportionate impact on the Fund. The Fund engages in active and frequent trading of its securities, which may result in increased transaction fees, reduced investment performance, and higher taxes. The Fund may invest in foreign or emerging market securities, which may be adversely affected by economic, political, or regulatory factors and subject to currency volatility and greater liquidity risk. The Fund may invest in derivatives, which are subject to greater liquidity, leverage, and counterparty risk. These factors can affect Fund performance. The fund performance history at this time is very limited; therefore, performance achieved during its initial period of investment operation may not be replicated over longer periods and may not be indicative of how the Fund will perform in the future.

The Fund's portfolio is actively managed and is subject to change.

INVESTMENT TEAM

Team Leader(s):

Devesh Karandikar
29 Years Industry Experience

Matthew R. DeCicco, CFA, Partner & Director
25 Years Industry Experience

Heidi A. Lawrence
23 Years Industry Experience

Samantha E. Shevins
24 Years Industry Experience

Supported By:

11 Investment Professionals
19 Years Avg. Industry Experience

FUND BASICS

Total Net Assets (\$M):³ \$8.8
Inception Date: 08/01/2019 (Class A)
Capital Gains Distribution: November
Dividend Frequency: Monthly
Minimum Initial Investment: \$1,500

³Includes all share classes.

EXPENSE RATIOS ¹	GROSS	NET [†]
Class A:	3.53%	1.03%
Class C:	4.28%	1.78%
Class F:	3.38%	0.78%
Class F3:	3.10%	0.60%
Class I:	3.28%	0.78%
Class R3:	3.78%	1.28%
Class R4:	3.53%	1.03%
Class R5:	3.28%	0.78%
Class R6:	3.10%	0.60%

[†]The net expense ratio is based on estimates for the current fiscal year and takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2025. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.

LORD ABBETT DISTRIBUTOR LLC

30 Hudson Street, Jersey City, NJ 07302-4804


lordabbett.com

888-522-2388

Copyright © 2024 by Lord Abbett Distributor LLC


All rights reserved.

REGIONAL ALLOCATION



Regional Allocation source: Lord Abbett and Bloomberg. Region classifications of countries are defined by Lord Abbett and may not be consistent with the MSCI region definitions. Country classifications of securities held within the universe of MSCI indexes are defined by MSCI. Country classifications of securities held by the portfolio only, and not included within the universe of MSCI indexes, are defined by Lord Abbett.

INDUSTRY ALLOCATION



* The MSCI ACWI Health Care Index
Industry allocations exclude cash therefore Fund percentage allocations may not equal 100%.

TEN LARGEST HOLDINGS

Eli Lilly & Co	8.6%	Natera Inc	3.2%
Novo Nordisk A/S	5.8%	Thermo Fisher Scientific Inc	2.7%
Boston Scientific Corp	3.6%	Argenx SE	2.5%
Intuitive Surgical Inc	3.4%	Regeneron Pharmaceuticals Inc	2.3%
Danaher Corp	3.3%	PROCEPT BioRobotics Corp	2.2%

Holdings are for informational purposes only and are not a recommendation to buy, sell, or hold any security.

GLOSSARY OF TERMS

Weighted Average Market Capitalization is the average market capitalization of all companies held in the portfolio, with each company weighted according to its percent held in the portfolio.

Price/Earnings Ratio is the weighted average of each holding's P/E ratio (price of a stock divided by its earnings per share).

The MSCI ACWI Health Care Index includes large and mid cap securities across 23 Developed Markets (DM) and 26 Emerging Markets (EM) countries. All securities in the index are classified in the Health Care as per the Global Industry Classification Standard.

The MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed or produced by MSCI.

Lipper Health/Biotechnology Funds Average is based on a universe of funds with similar investment objectives as the Fund. Source: Lipper Analytical Services.

The information provided is not directed at any investor or category of investors and is provided solely as general information about Lord Abbett's products and services and to otherwise provide general investment education. None of the information provided should be regarded as a suggestion to engage in or refrain from any investment-related course of action as neither Lord Abbett nor its affiliates are undertaking to provide impartial investment advice, act as an impartial adviser, or give advice in a fiduciary capacity. If you are an individual retirement investor, contact your financial professional or other fiduciary about whether any given investment idea, strategy, product or service may be appropriate for your circumstances.

[‡]The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Ratings do not take into account the effects of sales charges and loads.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Lord Abbett Funds. This and other important information is contained in the Fund's summary prospectus and/or prospectus. To obtain a prospectus or summary prospectus on any Lord Abbett mutual fund, contact your investment professional, Lord Abbett Distributor LLC at 888-522-2388 or visit us at lordabbett.com. Read the prospectus carefully before you invest.